Tag: Credible

How to Know if an Online Marketing Expert is Actually Credible

6 min read

Opinions expressed by Entrepreneur contributors are their own.

The Internet is filled with information — but only some of it is accurate. The rest of it ranges from unsupported opinions masquerading as fact to outright “fake news” from fraudsters who claim to have expert advice with credible data. In some cases, these sources are obvious in their lack of credibility, but others are more challenging to identify, thanks to slick websites and “deepfake” visual technology. That’s just the issues consumers face trying to discern what they should and shouldn’t believe. 

When entrepreneurs and business people seek advice about aspects of their business, such as online marketing, they might not know where to turn. With so many blogs, articles, ebooks and webinars from those claiming to be the most experienced digital marketers out there, how can you distinguish valuable information from worthless advice? 

It can

Read More

GardaWorld’s revived bid for G4S is cheap but at least credible

G4S has spent much of the past decade stumbling between blunders. Failure to take suitor GardaWorld seriously could prove to be another one.

The Canadian company went public with a potential £3bn takeover offer for the UK-listed outsourcer on Monday. It did much the same thing 17 months ago, when it announced it was in the early stages of considering an approach to G4S.

The way GardaWorld handled that mooted bid did little to lend it credibility. G4S said it did not even receive a request for information, let alone a bid proposal, in the month it took GardaWorld to pull out. The private equity-backed group was regarded then as too small and with too much leverage to be a serious bidder for G4S, with its bemusing behaviour put down to a strategic play for G4S’s cash handling business.

This time is different. G4S sold its cash business to Brink’s

Read More

New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson’s Portfolio (NASDAQ:NBIX)

I had previously expressed my concern that Neurocrine (NBIX) shares could remain weak given a lack of thesis-changing data catalysts on the horizon, and the shares have fallen another 17% since my last update. I see nothing wrong with the business, but the quality of the Ingrezza business is a known factor now and most of the company’s more exciting pipeline developments are still some distance away.

To that end, the recent presentations at the MDS Virtual Congress on the company’s NBIb-1817 Parkinson’s gene therapy program (licensed/partnered from Voyager (VYGR) and Ongentys (opicapone) are “nice to have” updates. I do believe that the lack of more robust positive data on the gene therapy program is a modest negative, though I also believe that the revenue potential of Ongentys remains somewhat underappreciated by investors.

I do continue to believe that Neurocrine is undervalued, but I also an ongoing risk that investors

Read More